136 results about "Staphylococcus sciuri" patented technology

The present invention provides ketolide derivatives, which can be used as antibacterial agents. In particular, compounds described herein can be used for treating or preventing conditions caused by or contributed to by Gram-positive, Gram-negative or anaerobic bacteria, more particularly against, for example, Staphylococci, Streptococci, Enterococci, Haemophilus, Moraxalla spp. Chlamydia spp., Mycoplasm, Legionella spp., Mycobacterium, Helicobacter, Clostridium, Bacteroides, Corynebaclerium, Bacillus or Enterobactericeae. Also provided are processes for preparing such ketolide derivatives, pharmaceutical compositions thereof, and methods of treating bacterial infections.

The invention discloses a preparing method of east Asia Tityus antibiotic peptide gene and appliance, which comprises the following steps: restructuring bacillus coli Escherichia coli DH5a/BmKAMP1, CCTCC NO: M207036; constructing east Asia Tityus ioterium cell cDNA library; choosing PCR method; sieving positive colony of scorpion antibiotic peptide gene from ioterium cDNA library; sequence-analyzing coding trait of antibiotic peptide gene; assuring amino acid sequence of the antibiotic peptide gene; adopting chemosynthesis antibiotic peptide; possessing inhibition of diverse density for Gram's bacterium. This antibiotic peptide possesses specificity and high active, which can be used as antibacterial drugs.

The invention belongs to the field of bioengineering and particularly relates to a Gene drive carrier and a construction method thereof. The construction method includes the steps of 1), artificiallysynthesizing a cap5A promoter and an sgRNA fragment; 2), amplifying a cas9 gene; 3), amplifying a plasmid skeleton; 4), amplifying an rpsL promoter; 5), assembling an empty carrier; 6), inserting a spacer targeted at the formula described; 7), constructing the carrier. In the method, a novel chromosome box recombinase CcrC2 and CRISPR-Cas9 technology are combined in an attempting manner, an SCCmeckiller carrier system, namely the Gene driver carrier is constructed, the Gene drive acts on methicillin-resistant staphylococcus aureus MRSA, staphylococcal chromosome box SCCmec is targeted to remove from the methicillin-resistant staphylococcus aureus MRSA, and methicillin-resistant genes are thereby eliminated.

The invention relates to a method for detecting staphylococcus aureus based on a nucleic acid chromatography biosensing technique. The method provided by the invention comprises the following steps: designing a loop-mediated isothermal amplification (LAMP) primer (SEQ ID NO:1-4) according to a virulence gene nuc of the staphylococcus aureus, and establishing a staphylococcus aureus detection method based on an LAMP nano enzyme sensor by combining with a nano nucleic acid test strip. The method provided by the invention can be successfully used for distinguishing viable bacterial cells and dead bacterial cells, and lower detection limit on the staphylococcus aureus can reach 10CFU/mL.

A method of preventing or treating staphylococcal bacterial infection in an individual is disclosed. A vaccine based on a conjugate the 336 polysaccharide antigen can be used for active protection in individuals who are to be subjected to conditions that place them at immediate risk of developing a bacterial infection, as would be case in the context of a catheterization or a surgical procedure. Alternatively, antibodies raised in response to the antigen can be used to treat or to provide passive protection to individuals. The method can be used in a population of patients at risk for infection by various species of Staphylococcus or various types of Staphylococcus aureus.

Monoclonal antibodies which can bind to the Fnbp protein of Staphylococcus aureus and which are generated from a peptide from the D2 region of fibronectin binding protein B (Fnbp) of S. aureus are provided which can be useful in the treatment and protection against infection from staphylococcal bacteria such as Staphylococcus aureus. The monoclonal antibodies of the invention are advantageous in that they bind S. aureus in high affinity and thus can be useful in the prevention of the adherence of staph bacteria to host cells by impairing or inhibiting the ability of S. aureus Fnbp to bind to fibronectin. Kits and methods of utilizing the monoclonal antibodies of the invention are also provided.

The present invention provides ketolide derivatives, which can be used as anti-bacterial agents. Compounds disclosed herein can be used for the treating or preventing conditions caused by or contributed to by gram positive, gram negative or anaerobic bacteria, more particularly against, for example, Staphylococci, Streptococci, Enterococci, Haemophilus, Moraxalla spp., Chlamydia spp., Mycoplasm, Legionella spp., Mycobacterium, Helicobacter, Clostridium, Bacteroides, Corynebacterium, Bacillus, Enterobactericeae or any combination thereof. Also provided are processes for preparing compounds disclosed herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods of treating bacterial infections.

A portion of the lysostaphin gene of Staphylococcus simulans has been cloned and overexpressed in the cytoplasm of E. coli to yield lysostaphin, in the absence of preprolysostaphin and prolysostaphin, under the transcriptional control of an IPTG-inducible promoter and a ribosome binding site. IPTG induction of the transformed host cells produces intracellular, soluble, mature lysostaphin (27 kDa), in the complete absence of preprolysostaphin and prolysostaphin. The mature lysostaphin so formed dose not require post-translational modification. The mature lysostaphin so formed can be used treat and prevent staphylococcal infections.

Provided herein are ketolide derivatives, which can be used as antibacterial agents. Compounds described herein can be used for treating or preventing conditions caused by or contributed to by gram positive, gram negative or anaerobic bacteria, more particularly against, for example, Staphylococci, Streptococci, Enterococci, Haemophilus, Moraxalla spp., Chlamydia spp., Mycoplasm, Legionella spp., Mycobacterium, Helicobacter, Clostridium, Bacteroides, Corynebacterium, Bacillus, Enterobactericeae, Propionibacterium acnes or any combination thereof. Also provided are processes for preparation of compounds described herein, pharmaceutical compositions thereof, and methods of treating bacterial infections.

The present invention discloses a lysostaphin compounded preparation. Said preparation comprises bacteria-killing effective quantity of lysostaphin and lysozyme. Said lysostaphin compounded preparation has higher bacteria-killing effect as compared with single lysostaphin, not only has the strong bacteria-killing action for Gram-positive bacterium and Gram-negative bacterium, but also has the good effect for killing the fungi of Candida albicans and red trichophyton, etc. It has high bacteria-killing activity and stability, does not produce drug resistance, and has no toxic side effect.

A protein isolated from Staphylococcus epidermidis having an approximate MW of 52 kD determined by SDS-PAGE and an N-terminal amino acid sequence (SEQ ID NO:1), and antigenic determinant-containing fragments of the protein, optionally coupled to an inert carrier or matrix, are disclosed. Disclosed are also a recombinant DNA molecule coding for the protein or the protein fragments; a vector comprising the DNA molecule or the corresponding RNA molecule; antibodies or antigen-binding peptides recognizing and specifically binding to the protein or protein fragment; use of the protein or protein fragment, or the vector, for the production of vaccines against Staphylococcal infections; use of the antibodies or antigen-binding peptides for the production of a medicament for passive immunization; a vaccine against Staphylococcal infections comprising the protein or protein fragment, or the vector, a medicament for passive immunization comprising the antibodies or antigen-binding peptides; and a method of prophylactic and/or therapeutic treatment of Staphylococcal infections.

The invention belongs to biological technique field, relates to small molecular inhibitor against staphylococci tryptophanyl-tRNA synthetase (WRS), molecular structure of the inhibitor shown in formula I, method of the inhibitor as medicament for preventive or treating relevant bacterial disease. Biochemical and biological experiments have shown that the inhibitor has strong binding force with target protein staphylococcus epidermidis or Staphylococcus aureus tryptophanyl-tRNA synthetase, can inhibit the activity of the synthetase, inhibit the growth of staphylococcus epidermidis Staphylococcus aureus. It has no toxicity to mammalian cell. The inventive inhibitor can be used for preparing medicament for treating disease caused by staphylococci, and preparing into disinfectant liquid.

The invention discloses a disinfection solution, which is characterized in that the solution has the following components based on weight proportion: 50-100PPM of nano-silver ions, 1-5% of polyvinylpyrrolidone, 1-5% of polyethylene glycol, and the remaining water. As the anti-bacterial rate is up to 99.99%, the invention can effectively kill, resist and inhibit Staphyloccocus aureus Rosenbach, Escherichia coli and other 650 kinds of bacteria and viruses to reduce the spreading rate of disease, and can be used in the disinfection of various environments.

This invention relates to a method for preparing lysostaphin and its derivatives. The method comprises: designing and synthesizing lysostaphin gene, inserting lysostaphin gene into the digestion site of expression vector (plasmid pET), transforming E. coli, screening positive clones, culturing, inducing the expression of target protein, collecting E. coli, lysing, centrifuging, collecting the supernatant, and purifying the supernatant through chromatography. The method has such advantages as simple process, high expression level, simple purification, high yield, soluble product, and no requirement for renaturation, and is suitable for mass production. The lysostaphin derivatives are obtained by modifying lysostaphin with polyethylene glycol, and have such advantages as low immunogenicity and long half value period. The lysostaphin and its derivatives are suitable for treating Staphylococcus infection in clinic.

The invention discloses a chemiluminescent enzyme-linked immunoassay detection kit for staphylococcal enterotoxin C. The contents of the kit comprise a staphylococcal enterotoxin C-resistant monoclonal antibody, a horseradish peroxidase-marked staphylococcal enterotoxin C-resistant detection antibody solution, a staphylococcal enterotoxin C series standard solution, a coating solution, a sealing solution, a cleaning solution, a chemiluminescent solution and a chemiluminescent enzyme-linked plate. The kit has the characteristics of high specificity, sensitivity and repeatability, and is suitable for monitoring diseases and quickly and quantitatively detecting staphylococcal enterotoxin C in foods and blood.

This invention discloses a purification technology for lysostaphin industry, which cultures supernatant purified lysostaphins from sphere bacilli containing the lysostaphin gene. Said method includes ionic exchange and drain chromatograph and needs two days only to process 45L sample, the total recovery rate is 50%, the specific activity is greater than 1000V/mg proteins and the purity is over 90% displayed on the non-recovery SDS-PAGE electrophoresis result.

The present invention discloses an immune chip for detecting staphylococcal enterotoxin and papaverina dn its preparation process. The immune chip has slide glass with surface treated with silane as aldehydation reagent and crosslinked with glutaraldehyde as double-function crosslinking reagent, and connected via covalent bond with the molecule of at least one kind of antibody staphylococcal enteriotoxin A antibody, staphylococcal enterotoxin B antibody, staphylococcal enterotoxin C antibody and papaverine antibody. The detection with the immune chip is simple, effective and low in cost.